培美曲塞联合铂类治疗恶性腹膜间皮瘤诊疗分析  

Pemetrexed combined with platinum to treat patients with malignant peritoneal mesothelioma

作　　者：刘娟[1] 李智可 勾红峰[2] 朱江[1] LIU Juan;LI Zhi-ke;GOU Hong-feng;ZHU Jiang(Department of Thoracic Oncology,West China Hospital,Sichuan University,Chengdu 610041,Sichuan,China;Department of Abdominal Oncology,West China Hospital,Sichuan University,Chengdu 610041,Sichuan,China)

机构地区：[1]四川大学华西医院胸部肿瘤科,四川成都610041 [2]四川大学华西医院腹部肿瘤科,四川成都610041

出　　处：《川北医学院学报》2019年第1期88-91,共4页Journal of North Sichuan Medical College

摘　　要：目的:回顾性分析恶性腹膜间皮瘤(malignant peritoneal mesothelioma,MPM)的临床病理特征,观察培美曲塞联合铂类治疗MPM的疗效。方法:收集确诊为MPM且一线接受培美曲塞联合铂类治疗的21例患者临床资料,回顾性分析并总结其临床、病理特点及疗效。结果:18例检测了CA125的患者中,13例(72.2%)增高。病理类型为上皮型的有19例,为肉瘤型/双相型的有2例。所有患者均接受了培美曲塞联合铂类的化疗方案,有效率为23.8%,疾病控制率为85.7%,全组中位生存时间为26个月。结论:MPM发病率低、恶性程度高,大部分患者会出现CA125升高,以培美曲塞为基础的化疗有助于延长晚期患者的生存。Objective:The clinical and pathological characteristics of malignant peritoneal mesothelioma(MPM) were retrospectively analyzed and to observe the efficacy of combination of pemetrexed combined with platinum in the treatment of MPM.Methods:The clinical data of 21 patients with MPM who received pemetrexed combined with platinum in first-line therapy were collected,and their clinical pathological characteristics and efficacy were retrospectively analyzed and summarized.Results:Of the 18 patients who tested for CA125,13(72.2%) increased.There were 19 epithelioid patterns and 2 sarcomatoid/mixed patterns.Pemetrexed combined with platinum was administered to all patients,the response rate was 23.8% and disease control rate was 85.7%,the median OS was 26 months.Conclusion:The incidence of MPM is low and it’s very malignant,CA125 is increased in most of patients.Pemetrexed-based chemotherapy could prolong the survival of patients with advanced stage.

关 键 词：恶性腹膜间皮瘤 疗效 培美曲塞 铂类 

分 类 号：R735.5[医药卫生—肿瘤]